- Dose range
- 2.5 → 15 mg/wk
- Route
- Subcutaneous injection, once weekly
- Indication(s)
- Type 2 diabetes
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| 1 | 2.5 mg | Weeks 1-4 | No glycemic control |
| 2 | 5 mg | 4+ weeks | Maintenance option |
| 3 | 7.5 mg | 4+ weeks | |
| 4 | 10 mg | 4+ weeks | Maintenance option |
| 5 | 12.5 mg | 4+ weeks | |
| 6 | 15 mg | Max |
Important notes
- This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- FDA-approved label dosing.
- Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. The April 14, 2026 FDA action restricted salt-form active ingredients.
References
- Mounjaro (brand tirzepatide) prescribing information / clinical literature.
- FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.